In a new set­back, FDA kicks back Acel­Rx’s ap­pli­ca­tion for pain med — shares tank again

An ac­ci­dent-prone Acel­Rx $ACRX has stum­bled in­to an­oth­er reg­u­la­to­ry ditch.

The biotech re­port­ed this morn­ing that the FDA re­ject­ed its ap­pli­ca­tion for Dsu­via (ARX-04), a …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER